SHR-A1811 Injection
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent or Metastatic Cervical Cancer
Conditions
Recurrent or Metastatic Cervical Cancer
Trial Timeline
Oct 11, 2025 → Aug 1, 2026
NCT ID
NCT07051486About SHR-A1811 Injection
SHR-A1811 Injection is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Recurrent or Metastatic Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07051486. Target conditions include Recurrent or Metastatic Cervical Cancer.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent or Metastatic Cervical Cancer were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07051486 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent or Metastatic Cervical Cancer